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Abstract
Background: To investigate the guidance selection of docetaxel (D), cisplatin (DDP) (C), and 5-fluorouracil (5-FU) (F)
as individual chemotherapy agents via joint detection of ERCC1, TUBB3, and TYMS genes in patients with advanced
gastric cancer (AGC).
Method: Clinical data of 120 patients with AGC who enrolled in our hospital between May 2009 and May 2012
were analyzed. These patients were randomly assigned to experimental and control groups. The mRNA expression of
ERCC1, TUBB3, and TYMS was measured by DNA chip technology in the experimental group. Different chemotherapies
were administered according to the mRNA expression levels of the three genes, while DCF chemotherapy was directly
applied to the control group. Correlation between the three genes’ mRNA levels, efficiency rate, the median time to
progression (MTP), median survival time (MST) and adverse reactions was evaluated.
Results: As a result, there was a significant correlation between ERCC1 and TUBB3 mRNA expression (P = 0.005), but no
obvious correlation between TUBB3 and TYMS or ERCC1 and TYMS. There was also no significant difference in the
efficiency rate of chemotherapy (50% versus 55%; P = 0.357) and the MTP (10 months versus 7 months; P = 0.091)
between the two groups. However, there was obvious significance in MST (13.7 months versus 11.6 months; P = 0.004).
Additionally, the experimental group provided us with a more effective way for controlling adverse reactions to
chemotherapy.
Conclusion: Combination regimen of D, C, and F in AGC patients according to their ERCC1, TUBB3, and TYMS mRNA
expression level may reduce adverse reactions and improve MST.
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Background
Gastric cancer, which ranks as the cancer with the second
highest mortality rate, is the fourth most common malig-
nant tumor overall [1]. The incidence and mortality of
gastric cancer is high in China, especially in Qinghai prov-
ince. However, most newly diagnosed patients tend to be
in the late stages [2-4]. At present, systemic chemotherapy
is the main treatment option for these patients [5-7].
However, the effectiveness of chemotherapy in advanced
gastric cancer (AGC) is less than 50%, and these patients
have a median survival time (MST) of six to nine months,
rarely exceed one year [8]. Although many chemotherapy
regimens in randomized studies have been examined,
there is no international standard for gastric cancer
treatment [5,9]. Previous reports have shown that ther-
apy using docetaxel and cisplatin (DPP) plus fluoroura-
cil (5-FU) improved survival of patients with advanced
cancer, but the clinical application was limited due to
the toxicity [10].
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The development of human genomics, pharmacogen-
omics, and tumor molecular biology shows a unique
genetic map [11]. The genetic differences relating to
drug sensitivity and resistance in patients have been
found by detecting genetic alterations in patients using
pharmacogenomics [12]. Subsequently, selection of ap-
propriate chemotherapeutic drugs will be benefited lead-
ing to efficacy improvement, reducing side effects, and
avoiding ineffective treatment. Chemotherapeutic toler-
ance and drug resistance are the main causes of chemo-
therapy failure in gastric cancer [13].
A number of drug-related genetic factors include 5-FU
metabolism-associated genes (for example, thymidylate
synthase (TYMS), deoxythymidylate kinase (DTYMK))
[14], taxol-related genes (Class III β-tubulin (TUBB3))
[15], and platinum-related genes (for example, excision
repair cross-complementation group (ERCC1) and breast
cancer 1, early onset (BRCA1)) [16]. ERCC1 group par-
ticipates in drug resistance in the response to platinum-
based chemotherapy [17]. Its mRNA expression level
has shown a negative correlation with platinum-based
cancer chemotherapy and survival [18]. Sensitivity to
platinum-based chemotherapy has been observed in pa-
tients with low ERCC1 expression, while resistance has
been noted in whose with high expression level [19,20].
The patients with tumors of high TUBB3 mRNA expres-
sion present with poorer treatment outcomes with
shorter MST on chemotherapy with anti-microtubule
drugs and vice versa [21,22]. TYMS encodes the rate-
limiting enzyme thymidylate synthase (TS), which is re-
sponsible for pyrimidine nucleotide synthesis and tumor
growth [23]. TS is also the target enzyme for 5-FU to
exert its cytotoxic effects [24]. The tumor patients with
low TYMS mRNA levels showed a better response with
longer MST on fluorine-based chemotherapy. Through
meta-analysis, Hu et al. [25] have pointed out that
TYMS is one of the useful predictive and prognostic
genetic factors.
Tumor drug resistance is controlled by a complex web
of gene networks. It has been observed that there are
obvious limitations to testing a single target gene. Predi-
cation of clinical drug efficacy for patients can be
achieved by detecting the expression pattern of a single
gene or marker [26]. Therefore, it is important to screen
drugs for patients by means of detecting target genes.
With the development of individualized treatment and
molecular detection, it is now possible for parallel deter-
mination of target genes.
In recent years, some studies have been performed to
identify biomarkers along with clinical outcomes as the
individual chemotherapy for AGC; this may improve
treatment efficacy and avoid unnecessary side effects.
However, few studies have indicated the efficiency of in-
dividual chemotherapy for AGC by detecting the mRNA
expression level of genes to guide the selection of spe-
cific drugs. To elucidate more insights into individual
chemotherapy for AGC, we investigated the guidance
selection of docetaxel (D), DDP (C), and 5-FU (F) as
individual chemotherapy via joint detection of ERCC1,
TUBB3, and TYMS genes. The results of this investiga-
tion might contribute to guiding therapy for chemother-
apy selection in patients with AGC.
Methods
Patient selection
Patients with AGC according to histopathology were se-
lected from the Department of Tumor, Internal Medicine
Affiliated Hospital of Qinghai University between May
2009 and May 2012. One hundred and twenty patients
aged 21 to 70 years old (28 patients in the ≤ 35-year-old
group; 92 patients in the 36- to 70-year-old age group;
median age was 59 years old) including 85 males and 35
females, were chosen for further investigation. The base-
line clinical characteristics are shown in Table 1 based on
American Joint Committee on Cancer (AJCC) TNM sta-
ging system (2010) [27]. The inclusion criteria were as fol-
lows: patients with AGC presenting a measurable primary
lesion, diameter ≥ 20 mm, chest radiograph showing ≥
Table 1 Baseline clinical characteristics of the two









Gender 120 60 60
Male 85 42 43 1
Female 35 18 17
Age
≤ 35 28 13 15 0.829
36 to 70 92 47 45
Phase
III C 42 22 20 0.848
IV 78 38 40
Tumor location
Proximal stomach 28 15 13 1
Gastric body 40 18 22
Distal stomach 52 27 25
ECOG score
0 to 1 46 24 22 0.851
2 74 36 38
Pathological type
Well differentiated 16 7 9 0.8
Moderately differentiated 28 15 13
Poorly differentiated 76 38 38
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20 mm, magnetic resonance imaging (MRI) (3.0 T) show-
ing ≥ 10 mm or computed tomography (CT) (256-slice)
showed ≥ 10 mm; survival estimates of Eastern Coopera-
tive Oncology Group (ECOG) ≤ 2 that have a median
survival of more than 3 months; patients with normal
peripheral blood count, no major organ damage, normal
ECG, no non-healing wounds. Patient participation was
voluntary and required signed informed written consent.
Patient exclusion criteria were as follows: pregnancy,
breast-feeding and female patients of childbearing age not
using contraception; uncontrolled acute infection; sup-
puration, chronic wound infection, and delayed wound
healing; patients with serious heart disease; neurological
disorder and mental illness; undifferentiated carcinoma
and squamous cell carcinoma.
The exit criteria were as follows: cases of severe drug-
related toxicity; inability to tolerate side effects; patients
withdrawing from the study; patients who researchers
believe should be withdrawn.
The enrolled patients with AGC in our study were ran-
domly assigned to two groups: the experimental group
and the control group. The mRNA expression of ERCC1,
TUBB3, and TYMS were measured by DNA chip technol-
ogy in the experimental group. Then, the experimental
group was divided into four subgroups according to the
mRNA expression of the three genes: low expression of a
single-gene subgroup, low expression of double-gene sub-
group, low expression of triple-gene subgroup, and non-
low expression of triple-gene subgroup.
Gene expression detection
DNA chip technology was used to investigate the ex-
pression patterns of genes based on hybridization of la-
beled RNA probes [28]. To elucidate the mRNA levels
of ERCC1, TUBB3, and TYMS in gastric cancer tissue,
the DNA chip technology was employed as described by
Liu et al. [29]. Firstly, total RNA was released from gas-
tric carcinoma in formalin-fixed paraffin-embedded tissue.
The targeted mRNA probe was bound to the microsphere.
Target and signal amplification was then performed by
hybridization reaction. Finally, the processed mRNA probe
were combined with streptavidin-phycoerythrin (SA-PE)
and analyzed by a Luminex 100 flow cytometer (Luminex
Corp., Austin, TX, USA). p2-microglobulin, transferrin
receptor, and TATA-box binding protein were used as
controls for housekeeping gene expression. The mean
fluorescence intensity (MFI) values of the background
were subtracted from the MFI values of the sample to
determine the net MFI, which represents the relative
mRNA expressions of ERCC1, TUBB3, and TYMS.
To estimate these three gene expression patterns in
patients over the whole distribution, the quartile method
was used. In this method, a percentage rate less than
37.5% denotes lower expression; from 37.5% to 62.5%
denotes mid-level expression, while more than 62.5%
denotes higher expression.
Chemotherapy regimens
The chemotherapy regimen comprising D, C and F was
administered to low (or mid-level) expression of ERCC1,
TUBB3, and TYMS patients respectively in the experi-
ment group. D, C, and F combination chemotherapy was
utilized for fourteen cases (low (or mid-level) expression
of ERCC1, TUBB3 and TUBB3); in pair-wise fashion, D
plus C was administered to seventeen cases (low (or mid-
level) expression of ERCC1 and TUBB3); D plus F was
administered to ten cases (low (or mid-level) expression of
TUBB3 and TYMS); C combined with F therapy was used
for eight cases (low (or mid-level) expression of ERCC1
and TYMS); isolated D, C, and F were given to six, three,
and two cases, respectively. The doses of D, C, and F in
the chemotherapy regimes were 75 mg/m2, 75 mg/m2,
and 750 mg/m2, respectively. The control-group patients
were given the combination chemotherapy of D, C, and F
(at same dose levels as the experiment groups). The effi-
cacy was tested for two periods of 21 days.
Evaluation of efficacy and indicator in patients
Short-term clinical effects in patients with solid tumors
were classified into complete response (CR), partial re-
sponse (PR), stable disease, and progressive disease (PD)
according to Response Evaluation Criteria in Solid Tu-
mors (RECIST) 1.1. CR and PR represent the effective
influence on patients, while PD represents the ineffective
impact on patients. Adverse reactions were divided into
grades 0 to IV based on National Cancer Institute Com-
mon Toxicity Criteria, version 3.0 (NCI-CTC 3.0). The
indices relating to patients’ survival were identified as
time to progression and overall survival time. Patient
follow-up was once every two months via telephone calls
after stopping treatment up until death.
Statistical method
Data were analyzed using SPSS software program ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA). The χ2 and
Fisher’s exact tests were carried out for count data. Exact
calculation of the R × C table used Monte Carlo. The
rank correlation test was then computed to reveal the
correlation between groups. The Kaplan-Meier analysis
provided survival estimates and the log-rank test was
used to compare survival curves for patients between
groups. Cox regression model analysis of factors poten-
tially related to survival was used to identify the inde-
pendent factors that may significantly affect survival. A
two-sided test (α = 0.05) was performed for all statistical
tests.
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Results
Correlation of ERCC1, TUBB3, and TYMS mRNA levels in
patients
To investigate the ERCC1, TUBB3, and TYMS mRNA
expression of patients in the experimental group, DNA
chip technology was performed. Results revealed that 36
(60.00%) and 16 (26.67%) patients showed low and mid-
level ERCC1 levels respectively. Thirty-three (55.00%)
and 15 (25.00%) patients were shown to have low and
mid-levels respectively of TUBB3 mRNA expression.
Twenty-seven (45.00%) and 15 (25.00%) patients yielded
low and mid-levels of TYMS mRNA. There were 18
(30.00%), 27 (45.00%), and 10 (16.67%) cases showing low
expression of single, double, and triple genes, respectively.
However, there were eight cases that showed high or
mid-level but not low expression of these three genes.
Rank correlation methods were then computed to iden-
tify the relationship between ERCC1, TUBB3, and TYMS
mRNA levels in all patients. As a result, there was a poorly-
correlated relationship between the mRNA levels of ERCC1
and TUBB3 (γ = 0.361, P = 0.005). Nevertheless, this pheno-
menon was not observed in mRNA levels of TUBB3 and
TYMS, or between ERCC1 and TYMS (P > 0.05).
Effectiveness of chemotherapy
Total effective rate of chemotherapy in 120 patients with
AGC was 52.50% (63/120). The chemotherapy showed
50.00% (30/60) and 55.00% (33/60) effectiveness rates in
the experiment group and control group, respectively.
However, despite small differences in chemotherapy ef-
fectiveness rate for the two groups, no significant differ-
ence was observed (χ2 = 0.301, P = 0.357).
We then proposed an exact Monte Carlo approach
to reveal the chemotherapy response among four sub-
groups of the experiment group (P = 0.002). As shown in
Table 2, the results indicated that no obvious difference
was found between the single-gene subgroup (low-level
expression) and those subgroups of the double gene (low-
level expression) and non-low expression of triple gene
(P = 0.721, P = 0.084, respectively). However, there was a
significant difference between the low expression of a sin-
gle gene and the low expression of triple gene (P = 0.025).
The double-gene subgroup with low or mid-level expres-
sion pattern significantly improved with chemotherapy
compared with the triple-gene subgroup with low or
mid-level expression (P = 0.001). The triple-gene subgroup
with low or mid-level expression also significantly improved
chemotherapeutic effectiveness in comparison with non-
low expression of triple gene (P < 0.001).
The MTP assay
As shown in Figure 1, median time to progression (MTP)
was analyzed to study the chemotherapeutic effect be-
tween the two groups. The results showed that the MTP
was 9 months for the 120 patients. In addition, the MTP
was ten months and seven months for the experiment
group and the control group, respectively. The log-rank
test demonstrated that there was no significant difference
between the two groups (χ2 = 2.849, P = 0.091).
The MST assay
As shown in Figure 2, the MST was then analyzed for all
patients with AGC. A 12-month MST was observed in
120 patients. The MST of the experimental group was
13.7 months, while for the control group was only
11.6 months. A statistically significant difference was ob-
served between the two groups (χ2 = 8.310, P = 0.004).
The result also showed that the experimental group had
a longer survival curve compared to the control group.
However, no significant difference in MST was found
between the four subgroups of the experiment group.
Comparison of adverse reactions
We observed that the types of adverse reaction were simi-
lar in all 120 patients with AGC. The types of adverse
reaction included hematologic toxicity, gastrointestinal re-
actions, neurotoxicity, and liver and kidney dysfunction.
Hematologic toxicity includes leukopenia, decrease in
hemoglobin, and thrombocytopenia. The patients in the
experimental group experienced hematologic toxicity of a
grade 1 to 2, which was better than the control group
which experienced grade 3 to 4. There was a significant
difference in hematologic toxicity between the two groups
(P = 0.048, P = 0.016, P < 0.001). Gastrointestinal reactions
exhibited included nausea, vomiting, and diarrhea. The
patients in the control group experienced gastrointestinal
reactions of a grade 3 to 4, worse than the experimental
group (P < 0.001, P = 0.041). The experimental group also
performed better regarding peripheral neurotoxicity, liver
damage, and kidney damage than the control group
(P = 0.01, P = 0.01, P = 0.01). There were no deaths in the
two groups relating to chemotherapy, but eight cases were
withdrawn due to adverse reactions to chemotherapy in




















P = 0.721 (a compared with b); P = 0.025 (a compared with c); P = 0.084
(a compared with d); P = 0.101 (b compared with c); P = 0.006 (b compared
with d); P < 0.001 (c compared with d).
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the control group compared with one in the experimental
group. Thus, compared with the control group, the
experimental group demonstrated a more effective way
for controlling adverse reactions from chemotherapy
for AGC patients.
Discussion
In this present study, 120 patients with AGC were enrolled
and then randomly assigned to experimental and control
groups. Different chemotherapy regimens (DCF, DC, CF,
DF, D, C and F chemotherapies) were administrated to 60
Figure 1 Kaplan-Meier survival curves for time to progression in patients with advanced gastric cancer.
Figure 2 The median survival curves of the patients with advanced gastric cancer.
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patients with AGC based on analysis test data of ERCC1,
TUBB3, and TYMS mRNA expression levels in the experi-
mental group. Meanwhile, the other 60 patients with AGC
directly received the DCF chemotherapy regimen. Then, we
evaluated the correlation between the three genes’ mRNA
levels, efficiency rate, MTP, MST and adverse reactions.
The results showed that there was a significant correlation
between ERCC1 and TUBB3 mRNA expression levels, but
no obvious correlation between TUBB3 and TYMS or
ERCC1 and TYMS. Also, there was no significant difference
in the efficiency rate of chemotherapy and MTP between
the two groups. However, there was an obvious significant
difference in MST. Additionally, the experimental group
demonstrated a more effective way for controlling adverse
reactions from chemotherapy.
An effective chemotherapy regimen is critical for AGC
[30]. Our results showed that the chemotherapy effect-
iveness was 50% (experimental group) in the DCF pro-
gram, or their combination. The rate is higher than a
phase III study from the V-325 group and also higher
than the research which involved 48 cases with DCF
regimen palliative chemotherapy conducted by Huang
et al. [21,31]. In our study, individualized chemotherapy
was used in AGC patients according to their mRNA
expression level of ERCC1, TUBB3, and TYMS, which may
account for the higher rate. Besides, lower therapeutic effect
in the V-325 study group may be influenced by the pres-
ence of more liver metastases or small sample size in phase
III. The response to DCF regimens may also be affected by
the number of chemotherapy cycles given to patients; a
consideration that warrants further investigation.
This study found that a better response to chemotherapy
occurs in TUBB3, TYMS, or ERCC1 low-expression sub-
groups compared with mid- or high-expression groups,
which is basically similar to conclusions drawn by Huang
et al. [21] and Lu et al. [31]. Serious chemotherapeutic side
effects, especially hematological toxicity, were observed in
the DCF-treated patients, which is similar to the V-325
study reported by Ajani et al. [32]. We can conclude that
DCF chemotherapy is effective, but with more side effects,
in the treatment of AGC. Lower adverse reaction rates
with good curative effect were shown in early stages under
chemotherapy regimen selection based on TUBB3, TYMS,
and ERCC1 mRNA expression levels in gastric cancer
patients.
This investigation showed that the MST and MTP was
11.6 and 7 months in the control group, which was
extended by 1.4 months in the V-325 study group, re-
spectively. Our results are consistent with a treatment
effect that has been reported by Hu et al. [25]. Shorter
survival in the V-325 study group may be due to the
inclusion of more patients with liver metastases and
fewer stage III patients. There was no significant differ-
ence in MTP between the experimental group and the
control group, but the MST was significantly longer in
the experimental group. This suggested that the chemo-
therapeutic drug extended the MST according to the
expression of target genes. Previous reports showed the
MST to be longer in patients with none or one resistance
gene than in patients with more than two resistance genes
[12]. In this study, there was no obvious difference among
the four experimental subgroups. However, the small
sample size here may influence the MST and a larger
sample size will need to be evaluated.
Conclusions
In conclusion, our study demonstrated that the combin-
ation regimen of D, C, and F in AGC patients according
to their ERCC1, TUBB3, and TYMS mRNA expression
level might reduce severe adverse reactions and improve
the MST. However, further investigation and a larger
clinical research sample are needed to further explore the
application of multiple genetic targets to chemotherapy
for patients with AGC.
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